Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie Hyman and Josh Lipton to break...
Johnson & Johnson reports earnings on Tuesday, which Shibutani says “typically kicks off earnings season for healthcare, but also for the large-cap pharmas. It really is the beachhead many read across sort of result” given the company’s pharmaceuticals and medical device businesses.
Last year company also predicted to provide an updated full year outlook after its $1.7 billion acquisition of the wave, which develops a number of treatments for heart failure with just a few minutes left to the closing bell on Wall Street.Joining us now, Chris Shibutani Goldman Sachs, senior biotechnology analyst in global investment research, Chris, it's great to see you here.
The company has been exposed to a bit of an overhang related to long standing litigation concerns to related injury claims.We would argue that they're probably approaching towards the later innings and if we can get some clarity on the resolution, that would be very reassuring for investors. Um, the company has already been sort of embarking on a, I guess you would call it a turnaround project for itself.Yeah, I think when you look at stock performance for Pfizer, it naturally peaked several years back at the height of the pandemic where the contributions the company made to address the COVID pandemic with a vaccine and the therapeutic packs of it were certainly tremendous.
I do think that attention to some of these issues does heighten the level of urgency and that's probably not a bad thing anytime the company is trying to address some of the challenges, Chris, always great to see you and have you on the show.On Friday in Colorado, former President Donald Trump announced 'Operation Aurora' a plan that invokes the Alien Enemies Act of 1798.
Chris Shibutani Goldman Sachs Market Domination Johnson & Johnson Stock Performance
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Johnson & Johnson discontinues dengue drug studyJohnson & Johnson said on Friday it will discontinue its mid-stage field study evaluating the efficacy of its antiviral drug candidate for the prevention of ...
Read more »
Will AI be a bust? A Wall Street skeptic rings the alarmThe head of stock research at Goldman Sachs continues to question the potential
Read more »
Goldman, BlackRock Warn Europe’s Stock Rally Faces Tough Hurdles(Bloomberg) -- European stocks face a series of hurdles to extend their 2024 rally after hitting another record high this week.Most Read from...
Read more »
Goldman Sachs reiterates bullish view on gold prices amid Fed rate-cut hopesGold prices rose to an all-time high at $2,589.6 an ounce on Monday, supported by a weaker dollar and the prospect of a big rate reduction by the Fed...
Read more »
Goldman Says Gold May Dip If Fed Opts for Quarter-Point Rate Cut(Bloomberg) -- Gold may face a minor, near-term setback if the Federal Reserve opts for just a 25-basis-point cut this week, but the metal will subsequently ...
Read more »
Kinaxis hires Goldman Sachs for financial advice – but board doesn’t seem keen on a saleExecuting on strategic plan ‘best path’ to maximize shareholder value, board says as chairman Robert Courteau promoted to executive role
Read more »